Anemia Defisiensi B12 (Kobalamin)

01Pathophysiology

Vitamin B12 (cobalamin) serves as an essential cofactor for two critical enzymatic reactions in the body. Understanding these two pathways is the key to understanding why B12 deficiency produces both hematologic and neurologic disease, and why this combination is a recurring theme in exam vignettes.

The first reaction involves methionine synthase, which converts homocysteine to methionine. This reaction simultaneously regenerates tetrahydrofolate (THF), the active form of folate required for thymidine synthesis and ultimately DNA synthesis. When B12 is absent, THF becomes trapped in its inactive methylated form (the so-called "folate trap"), and DNA synthesis stalls. Cells that divide rapidly, such as hematopoietic precursors in the bone marrow, are affected first. The result is megaloblastic change: nuclear maturation lags behind cytoplasmic maturation, producing abnormally large red cell precursors (megaloblasts) that undergo premature destruction within the marrow. This phenomenon is called ineffective erythropoiesis and explains the paradox of a hypercellular marrow with peripheral cytopenia. It also explains why LDH and indirect bilirubin are elevated, mimicking a hemolytic process.

The second reaction involves methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA, a step in odd-chain fatty acid metabolism. When this enzyme cannot function due to B12 deficiency, methylmalonic acid (MMA) accumulates. The buildup of abnormal fatty acids disrupts myelin synthesis in the nervous system, leading to the hallmark neurologic complication: subacute combined degeneration of the spinal cord. This condition involves demyelination of the posterior columns (carrying vibration and proprioception) and the lateral corticospinal tracts (carrying motor signals). This is why patients present with a combination of sensory ataxia (loss of position sense, positive Romberg) and upper motor neuron signs (spasticity, hyperreflexia, extensor plantar responses). Peripheral neuropathy can also occur, adding a lower motor neuron component that makes the clinical picture complex.

A critical teaching point: the neurologic damage from B12 deficiency can occur independently of anemia. A patient can present with a normal hemoglobin and still have devastating subacute combined degeneration. Exam writers test this concept frequently.

The dietary source of B12 is exclusively animal products (meat, dairy, eggs). Absorption requires a multi-step process: gastric acid and pepsin release B12 from food proteins, and B12 then binds to R-binder (haptocorrin) in saliva. In the duodenum, pancreatic proteases cleave the R-binder, and B12 transfers to intrinsic factor (IF), which is produced by gastric parietal cells. The B12-IF complex is absorbed in the terminal ileum via cubilin receptors. Any disruption along this chain (autoimmune parietal cell destruction, gastrectomy, ileal resection, Crohn disease of the terminal ileum, bacterial overgrowth that consumes B12, or tapeworm infection) can produce deficiency.

Pernicious anemia, the autoimmune destruction of parietal cells with resultant loss of intrinsic factor, is the most testable and most commonly tested cause.

02Classification and Clinical Manifestation

By Etiology

By Clinical Manifestation

The neurologic findings in B12 deficiency follow a predictable pattern. Symptoms typically begin in the lower extremities (peripheral neuropathy, loss of vibration sense at the toes) and ascend. On exam, you may find diminished ankle reflexes (from peripheral neuropathy) coexisting with upgoing toes (from corticospinal tract involvement).

03Diagnostic Workup

The workup begins with a CBC and peripheral blood smear when a patient presents with fatigue and macrocytosis. The smear is where you find the pathognomonic clue: hypersegmented neutrophils. A single neutrophil with 6 or more lobes, or at least 5% of neutrophils with 5 lobes, is considered diagnostic of megaloblastic anemia. This finding is not seen in other causes of macrocytosis (alcohol, hypothyroidism, liver disease, myelodysplastic syndrome), making it a powerful discriminator on exam questions.

Once megaloblastic anemia is identified, the next step is to determine whether the cause is B12 deficiency or folate deficiency, since both produce identical hematologic findings. Order a serum B12 level and a serum folate level. If the B12 is clearly low (< 200 pg/mL), the diagnosis is established. However, B12 levels between 200 and 400 pg/mL are considered indeterminate, and this is where the metabolite levels become essential.

The critical distinguishing test is methylmalonic acid (MMA):

• B12 deficiency: both MMA and homocysteine are elevated

• Folate deficiency: homocysteine is elevated, but MMA is normal

This distinction is one of the highest-yield facts for the exam. MMA is elevated only in B12 deficiency because the methylmalonyl-CoA mutase reaction is B12-dependent and folate-independent. Homocysteine is elevated in both because the methionine synthase reaction requires both B12 and folate.

Once B12 deficiency is confirmed, the next question is why. In a patient with risk factors for pernicious anemia (elderly patient, coexisting autoimmune disease), order anti-intrinsic factor antibodies. This is the most accurate test for pernicious anemia. It has moderate sensitivity (~60%) but very high specificity (>95%), so a positive result confirms the diagnosis. Anti-parietal cell antibodies are more sensitive but less useful in isolation because they can be positive in other conditions (such as chronic atrophic gastritis without B12 deficiency). The Schilling test is historical and no longer routinely available; do not select it as an answer on modern exam questions.

04Management and Treatment

Acute management depends on the cause of deficiency. For pernicious anemia, malabsorption, or neurologic involvement, the route must be intramuscular because oral absorption is unreliable. The standard regimen is cyanocobalamin 1000 mcg IM daily for 7 days, followed by weekly injections for 4 weeks, then monthly injections indefinitely. In patients with neurologic symptoms, some protocols recommend more aggressive initial loading (1000 mcg IM every other day for up to 3 weeks) to maximize early nervous system repair.

For patients with dietary deficiency and intact intrinsic factor and ileal function, high-dose oral supplementation (1000 to 2000 mcg daily) is effective. Even though only about 1% of oral B12 is absorbed via passive diffusion (without intrinsic factor), high doses are sufficient to overcome this when absorption mechanisms are intact.

Monitoring the response is critical and highly testable. After starting B12 replacement:

• Reticulocyte count should begin to rise within 5 to 7 days (reticulocyte crisis), peaking at about 7 to 10 days. This is the earliest sign of response and a commonly tested timeline.

• Hemoglobin normalizes over 6 to 8 weeks.

• Neurologic symptoms may improve over months, but damage that has been present for more than 6 months may be irreversible.

Electrolyte monitoring is important during the initial treatment phase. As the bone marrow resumes active erythropoiesis, there is rapid uptake of potassium into newly forming cells. This can cause hypokalemia, which must be monitored and corrected. This is an exam trap: a patient on B12 replacement who develops cardiac arrhythmias or muscle weakness may be experiencing treatment-related hypokalemia.

The single most important management pearl for exam purposes is the folate-B12 interaction: administering folate alone to a patient with undiagnosed B12 deficiency will correct the anemia (because folate can bypass the folate trap to some degree and restore DNA synthesis), but it will not treat and may actually worsen the neurologic damage. This is because the MMA-related demyelination pathway is folate-independent. Therefore, you must always check B12 levels before giving folate supplementation. If both are low, replace B12 first. This concept is among the most frequently tested in hematology.

Contraindications and cautions: There are no absolute contraindications to B12 replacement. In patients with Leber hereditary optic neuropathy, cyanocobalamin is avoided (hydroxocobalamin is used instead), but this is a rare scenario.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on B12 deficiency questions is by confusing it with folate deficiency. Both produce an identical hematologic picture, and the vignette may be deliberately vague about dietary history. The single differentiating lab value is methylmalonic acid: if MMA is elevated, it is B12 deficiency regardless of the folate level. If MMA is normal and homocysteine is elevated, it is folate deficiency. This is a straightforward question, but students fail it by not ordering MMA or by misremembering which metabolite is unique to which deficiency.

The second major trap is the folate correction pitfall. A vignette may describe a patient with macrocytic anemia and neurologic symptoms who was given folate and whose anemia improved, but the neurologic symptoms worsened. The student must recognize that folate was given without first checking B12, and that this corrected the hematologic abnormality while allowing the neurologic damage to progress unchecked. The correct answer in such a scenario is to check B12 and MMA levels and start intramuscular B12 immediately.

Third, students must recognize that neurologic symptoms can present without anemia. A vignette describing a patient with paresthesias, gait instability, and a normal CBC is still consistent with B12 deficiency. The peripheral smear may show subtle macrocytosis or hypersegmented neutrophils even when the hemoglobin is within normal limits, and MMA will be elevated.

Fourth, remember the monitoring trap. After initiating B12 replacement, the expected response is a reticulocyte count rise within 5 to 7 days. If the question asks what to check after starting treatment, the answer is reticulocyte count, not a repeat B12 level. Additionally, watch for the hypokalemia complication during treatment, as rapid erythropoiesis depletes serum potassium.

Finally, when the vignette presents an elderly patient with macrocytic anemia, an autoimmune condition (such as Hashimoto thyroiditis or type 1 diabetes), and glossitis, the diagnosis is almost certainly pernicious anemia, and the confirmatory test is anti-intrinsic factor antibodies, not anti-parietal cell antibodies. This distinction in antibody testing is frequently tested and frequently missed.

The core competency being assessed in B12 deficiency questions is threefold: the ability to distinguish B12 from folate deficiency using metabolite levels, the understanding that neurologic and hematologic manifestations are driven by separate biochemical pathways, and the recognition that improper treatment (folate alone) can cause harm.